BioNexus Gene Lab shares surge 45.61% premarket after securing $500M equity facility to fund diagnostics, CDMO expansion, and therapeutics.

BioNexus Gene Lab surged 45.61% in premarket trading following the announcement of a $500 million equity facility with ARC Group International. The 36-month agreement provides discretionary capital to advance the VitaGuard MRD platform commercialization, CDMO expansion, and therapeutic development. The deal includes a one-time 175,000-share fee at $4.32 and restricts ARC’s ownership to 9.99%, mitigating short-term dilution concerns. The facility complements BGLC’s existing $20 million ATM program, enhancing financial flexibility while emphasizing milestone-driven capital deployment. CEO Sam Tan highlighted the strategic importance of the funding for Southeast Asia’s precision oncology market, aligning with recent licensing agreements and CDMO initiatives. The move signals strong investor confidence in the company’s growth trajectory and operational execution.